Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nevirapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nevirapine SCHEMBL3318 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL30267890 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL29614675 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL29393780 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL6562884 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL5175341 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL1923903 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL8151939 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| SCHEMBL9704195 | 0.95 | ALDH1A1 (0.91) | ALDH1A1LMNAPOLBADORA3MAPK1 | |
| Nevirapine SCHEMBL28679264 | 0.94 | ALDH1A1 (0.89) | ALDH1A1LMNAPOLBADORA3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478324-A1 | ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME | GlaxoSmithKline Intellectual Property (No.2) Limited (GB) | 2019-05-08 | — | — | EP | disclosed |
| EP-3377896-A1 | HIGH-THROUGHPUT IMAGING-BASED METHODS FOR PREDICTING CELL-TYPE-SPECIFIC TOXICITY OF XENOBIOTICS WITH DIVERSE CHEMICAL STRUCTURES | Agency For Science, Technology And Research (SG) | 2018-09-26 | — | — | EP | disclosed |
| EP-3328875-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-06-06 | — | — | EP | disclosed |
| EP-3317271-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-05-09 | — | — | EP | disclosed |
| WO-2018002902-A1 | ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | WO | disclosed |
| WO-2017130156-A1 | INGENOL ANALOGS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017091147-A1 | HIGH-THROUGHPUT IMAGING-BASED METHODS FOR PREDICTING CELL-TYPE-SPECIFIC TOXICITY OF XENOBIOTICS WITH DIVERSE CHEMICAL STRUCTURES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017017607-A1 | BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017002064-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-05 | — | — | WO | disclosed |
| WO-2013076586-A2 | SYSTEMS, METHODS, AND COMPUTER PROGRAM PRODUCTS FOR GUIDING THE SELECTION OF THERAPEUTIC TREATMENT REGIMENTS | ADVANCED BIOLOGICAL LABORATORIES SA (LU) | 2013-05-30 | — | — | WO | disclosed |
| CN-1592684-A | Methods for qualitative and quantitative analysis of cells and related optical bio-disc systems | BURSTEIN TECHNOLOGIES INC (US) | 2005-03-09 | — | — | CN | disclosed |
| EP-1480772-A2 | METHODS FOR QUALITATIVE AND QUANTITATIVE ANALYSIS OF CELLS AND RELATED OPTICAL BIO-DISC SYSTEMS | Burstein Technologies, Inc. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| CN-1532290-A | Path and method for monitoring non nucleotide reverse transcriptive enzyme inhibitor anti retrovirus therapy | 病毒科学公司 | 2004-09-29 | — | — | CN | disclosed |
| WO-2004062613-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20030129665-A1 | Methods for qualitative and quantitative analysis of cells and related optical bio-disc systems | VINDUR TECHNOLOGIES, INC. (NO) | 2003-07-10 | — | — | US | disclosed |
| US-20030092145-A1 | Viral vaccine composition, process, and methods of use | IMMUNITOR USA INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003021223-A2 | METHODS FOR QUALITATIVE AND QUANTITATIVE ANALYSIS OF CELLS AND RELATED OPTICAL BIO-DISC SYSTEMS | BURSTEIN TECHNOLOGIES, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| CN-1311823-A | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy | VIROLOGIC INC (US) | 2001-09-05 | — | — | CN | disclosed |
| WO-2001054717-A1 | VACCINE COMPOSITION, PROCESS AND METHODS | JIRA VIC (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | ALDH1A1 483/4885LMNA 3550/4885POLB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.